What are ADC's

Our services

ADC Review
is made possible by:

NCT01577758 (Clinical Trial/ Indusatumab vedotin / MLN0264)

Study Title
Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C (NCT01577758)

Trial Description
This is an Open-Label, Multicenter, Dose Escalation, First-in-Human Study of MLN0264 (Indusatumab vedotin) in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C.

This trial is sponsored by  Millennium Pharmaceuticals[1]

Study Data

  • Condition: Advanced Gastrointestinal Malignancies
  • Interventions:
    • Drugs used in this trial
      • MLN0264 (Indusatumab vedotin)
  • Phase: I
  • Enrollment: 41
  • Start: June 2012
  • Completion: February 2014
  • Last verified: October 2014

Study Schematic 

Screen Shot 2016-07-20 at 4.02.13 PM

Click here to Return to Drug map

Last Editorial review: July 9, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar